Senl-T7

PreclinicalCell therapy

HHebei Senlang Biotechnology Inc., Ltd.

Senl-T7 is one of 75 biologic programs targeting Lymphoblastic Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoblastic LymphomaActive, not recruiting

LymphomaActive, not recruiting

Lymphoblastic LymphomaPreclinical

Active, not recruiting

LymphomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

2 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Refractory

NCT05626400

Clinical

Trials by Indication[1]

Refractory1 trial

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Recruiting·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT05626400·100 enrolled

Lymphoblastic Lymphoma1 trial

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04916860·100 enrolled

Lymphoma1 trial

Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04928105·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Senl-T7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Senl-T7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Senl-T7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hebei Senlang Biotechnology Inc., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: HHebei Senlang Biotechnology Inc., Ltd.

Senl-T7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Refractory1 trial

Lymphoblastic Lymphoma1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News